Human BMP7/OP-1 ORF/cDNA clone-Adeno-associate virus(AAV) particle (NM_001719)
Cat. No.: vGMAAV000461
Pre-made Human BMP7/OP-1 Adeno-associated virus particle for BMP7 in-vivo study, mechanism of action (MOA) research and BMP7-associated gene therapy development.
At GM Vector Core (GMVC), we stand at the forefront of custom AAV development and produce distinct grades of AAVs employing state-of-the-art methodologies. Uncover more about our expertise.
Go to
BMP-7/BMP7/BMP7/OP-1 products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | AAV serotype | AAV Grade | AAV quantity |
| vGMAAV000461 | Human BMP7 Adeno-associate virus(AAV) particle | AAV1, AAV2, AAV2 variant (Y444F), AAV2 variant (Y272F, Y444F, Y500F, Y730F), AAV2 variant (Y444F, Y730F, Y500F, Y272F, Y704F, Y252F), AAV2 variant(AAV2.7m8), AAV5, AAV6, AAV8, AAV8-1m, AAV8-2m, AAV8 variant (Y733F, Y447F, Y275), AAV9, AAV-Rh.10, AAV-DJ, AAV-DJ/8, AAV-Retro (Retrograde), AAV9-PHP.B, AAV9-PHP.eB, AAV9-PHP.S, AAV-BR1, AAV-2i8, AAV-SIG, AAV-VEC, AAV4, AAV6.2, AAV6.2FF | Pilot Grade | 1.0E+12VG/ml |
| 5.0E+12VG/ml | ||||
| 1E+13VG/ml | ||||
| 5E+13VG/ml | ||||
| 1E+14VG/ml | ||||
| Research Grade | 1.0E+12VG/ml | |||
| 5.0E+12VG/ml | ||||
| 1E+13VG/ml | ||||
| 5E+13VG/ml | ||||
| 1E+14VG/ml | ||||
| GMP-like Grade | inquiry | |||
| GMP Grade | inquiry |
Product Description
| Catalog ID | vGMAAV000461 |
| Gene Name | BMP7 |
| Accession Number | NM_001719 |
| Gene ID | 655 |
| Species | Human |
| Product Type | Adeno-associate virus(AAV) particle (overexpression) |
| Insert Length | 1296 bp |
| Gene Alias | OP-1 |
| Fluorescent Reporter | ZsGreen |
| Mammalian Cell Selection | Null |
| Fusion Tag | 3xflag (C-Terminal) |
| Promoter | CMV |
| Resistance | Amplicin |
| ORF Nucleotide Sequence | ATGCACGTGCGCTCACTGCGAGCTGCGGCGCCGCACAGCTTCGTGGCGCTCTGGGCACCCCTGTTCCTGCTGCGCTCCGCCCTGGCCGACTTCAGCCTGGACAACGAGGTGCACTCGAGCTTCATCCACCGGCGCCTCCGCAGCCAGGAGCGGCGGGAGATGCAGCGCGAGATCCTCTCCATTTTGGGCTTGCCCCACCGCCCGCGCCCGCACCTCCAGGGCAAGCACAACTCGGCACCCATGTTCATGCTGGACCTGTACAACGCCATGGCGGTGGAGGAGGGCGGCGGGCCCGGCGGCCAGGGCTTCTCCTACCCCTACAAGGCCGTCTTCAGTACCCAGGGCCCCCCTCTGGCCAGCCTGCAAGATAGCCATTTCCTCACCGACGCCGACATGGTCATGAGCTTCGTCAACCTCGTGGAACATGACAAGGAATTCTTCCACCCACGCTACCACCATCGAGAGTTCCGGTTTGATCTTTCCAAGATCCCAGAAGGGGAAGCTGTCACGGCAGCCGAATTCCGGATCTACAAGGACTACATCCGGGAACGCTTCGACAATGAGACGTTCCGGATCAGCGTTTATCAGGTGCTCCAGGAGCACTTGGGCAGGGAATCGGATCTCTTCCTGCTCGACAGCCGTACCCTCTGGGCCTCGGAGGAGGGCTGGCTGGTGTTTGACATCACAGCCACCAGCAACCACTGGGTGGTCAATCCGCGGCACAACCTGGGCCTGCAGCTCTCGGTGGAGACGCTGGATGGGCAGAGCATCAACCCCAAGTTGGCGGGCCTGATTGGGCGGCACGGGCCCCAGAACAAGCAGCCCTTCATGGTGGCTTTCTTCAAGGCCACGGAGGTCCACTTCCGCAGCATCCGGTCCACGGGGAGCAAACAGCGCAGCCAGAACCGCTCCAAGACGCCCAAGAACCAGGAAGCCCTGCGGATGGCCAACGTGGCAGAGAACAGCAGCAGCGACCAGAGGCAGGCCTGTAAGAAGCACGAGCTGTATGTCAGCTTCCGAGACCTGGGCTGGCAGGACTGGATCATCGCGCCTGAAGGCTACGCCGCCTACTACTGTGAGGGGGAGTGTGCCTTCCCTCTGAACTCCTACATGAACGCCACCAACCACGCCATCGTGCAGACGCTGGTCCACTTCATCAACCCGGAAACGGTGCCCAAGCCCTGCTGTGCGCCCACGCAGCTCAATGCCATCTCCGTCCTCTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACAGAAACATGGTGGTCCGGGCCTGTGGCTGCCACTAG |
| ORF Protein Sequence | MHVRSLRAAAPHSFVALWAPLFLLRSALADFSLDNEVHSSFIHRRLRSQERREMQREILSILGLPHRPRPHLQGKHNSAPMFMLDLYNAMAVEEGGGPGGQGFSYPYKAVFSTQGPPLASLQDSHFLTDADMVMSFVNLVEHDKEFFHPRYHHREFRFDLSKIPEGEAVTAAEFRIYKDYIRERFDNETFRISVYQVLQEHLGRESDLFLLDSRTLWASEEGWLVFDITATSNHWVVNPRHNLGLQLSVETLDGQSINPKLAGLIGRHGPQNKQPFMVAFFKATEVHFRSIRSTGSKQRSQNRSKTPKNQEALRMANVAENSSSDQRQACKKHELYVSFRDLGWQDWIIAPEGYAAYYCEGECAFPLNSYMNATNHAIVQTLVHFINPETVPKPCCAPTQLNAISVLYFDDSSNVILKKYRNMVVRACGCH |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
|---|---|---|
| Target Antibody | GM-Tg-g-T50289-Ab | Anti-BMP7/ OP-1 functional antibody |
| Target Antigen | GM-Tg-g-T50289-Ag | BMP7 protein |
| Cytokine | cks-Tg-g-GM-T50289 | bone morphogenetic protein 7 (BMP7) protein & antibody |
| ORF Viral Vector | pGMLV000318 | Human BMP7 Lentivirus plasmid |
| ORF Viral Vector | pGMLV000319 | Human BMP7 Lentivirus plasmid |
| ORF Viral Vector | pGMAAV000461 | Human BMP7 Adeno-associate virus(AAV) plasmid |
| ORF Viral Vector | pGMAP000439 | Human BMP7 Adenovirus plasmid |
| ORF Viral Vector | pGMLP-SPh-070 | Human BMP7 Lentivirus plasmid |
| ORF Viral Vector | pGMAP-SPh-210 | Human BMP7 Adenovirus plasmid |
| ORF Viral Vector | vGMLV000318 | Human BMP7 Lentivirus particle |
| ORF Viral Vector | vGMLV000319 | Human BMP7 Lentivirus particle |
| ORF Viral Vector | vGMAAV000461 | Human BMP7 Adeno-associate virus(AAV) particle |
| ORF Viral Vector | vGMAP000439 | Human BMP7 Adenovirus particle |
| ORF Viral Vector | vGMLP-SPh-070 | Human BMP7 Lentivirus particle |
| ORF Viral Vector | vGMAP-SPh-210 | Human BMP7 Adenovirus particle |
Target information
| Target ID | GM-T50289 |
| Target Name | BMP-7/BMP7 |
|
Gene Group Identifier (Target Gene ID in Homo species) |
655 |
| Gene ID |
100050299 (Equus caballus), 101094168 (Felis catus), 12162 (Mus musculus), 477270 (Canis lupus familiaris) 540595 (Bos taurus), 655 (Homo sapiens), 696948 (Macaca mulatta), 85272 (Rattus norvegicus) |
| Gene Symbols & Synonyms | BMP7,Bmp7,OP1,OP-1,BMP-7 |
| Target Alternative Names | BMP-7,BMP7,Bmp7,Bone morphogenetic protein 7,OP-1,OP1,Osteogenic protein 1 (OP-1) |
| Uniprot Accession |
P18075,P23359,P34819
Additional SwissProt Accessions: P23359,P34819,P18075 |
| Uniprot Entry Name | |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | Therapeutics Target, Cytokine Target |
| Disease | cancer |
| Disease from KEGG | Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Axon guidance, Hippo signaling pathway |
| Gene Ensembl | ENSECAG00000002918, ENSMUSG00000008999, ENSCAFG00845029691, ENSBTAG00000015362, ENSG00000101144, ENSMMUG00000004074 |
| Target Classification | Tumor-associated antigen (TAA) |
About GMVC

GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.


